Interpace Biosciences, Inc. develops and sells clinical diagnostic and pharmaceutical services. The company offers PancraGEN, a molecular test for pancreatic cysts and pancreaticobiliary solid lesions; ThyGenX, an expanded oncogenic mutation panel for detecting malignant thyroid nodules; ThyraMIR, and RespriDx, a genomic test that can be used to distinguish metastatic from recurrent lung cancer. The firm was founded in 1986 by John P. Dugan, based in Parsippany, New Jersey.
IDXG Stock Profile
The stock’s lowest price of the day was 1.02 on January 7, 2023, an increase of 11.11 percent from the start of the trading day. Interpace Biosciences has an extremely high probability of encountering financial difficulties soon. Investors have also seen negative returns in the last 90 days. We use our scoring structure to determine the daily stock ratings for Interpace Biosciences.
Based on performance scores calculated from October 9, 2022, to January 7, 2023.
Interpace Biosciences, Inc. has 4.27 million shares outstanding; 47.35 thousand have been shorted by individual and institutional investors, requiring 0.19 days to cover.
IDXG Stock Accentuates and Ownership
Most rational investors perceive market volatility as an opportunity to purchase at favorable prices or sell short against a negative trend. Interpace Biosciences investment highlights are automatically generated signals that are significant enough to either supplement or challenge your investment judgment. These highlights might assist you in comprehending the position you are entering and preventing expensive mistakes.
Interpace Biosciences analysts offer their recommendations after researching the company’s financial statements, interviewing its executives and customers, or taking part in conference calls. Interpace Biosciences currently has a buy rating based on an ongoing consensus estimate among analysts.
Interpace Biosciences’ consensus evaluation is calculated by averaging the projections of all analysts covering the company.
Biosciences acquire a substantial proportion of its outstanding shares from insiders. Insiders are CEOs, other business officers, directors, and institutional investors who own at least 10 percent of the company’s shares.
It is prudent to examine whether each of these insiders has purchased or sold shares in the past few months due to the substantial amount of stock held by insiders. The public owns 71.88% of the company, while insiders own 28.12%.
IDXG Stock Assessment
Interpace Biosciences’ target price will likely exceed its current price within 90 days based on a normal probability distribution. The probability density function of Interpace Biosciences indicates how likely it is for the company’s over-the-counter shares to fall within a given price range within the next 90 days.
Interpace Biosciences has a beta of 0.2716, indicating that when market returns improve, Interpace Biosciences’ average returns may rise slower than the benchmark. The predicted loss on owning Interpace Biosciences should be significantly less during a weak market. In addition, the company has a negative alpha, which suggests that the risk involved is not worth it. There is a wide gap between Interpace Biosciences and the NYSE Composite.
IDXG Stock Analyzing Risk
If you are conducting a pricing study of Interpace Biosciences, look for market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other essential factors. Interpace Biosciences’ operational health can be assessed using a variety of methods. To forecast the likelihood of future price fluctuations, Interpace Biosciences analyzes previous and current price behavior. To determine what factors influence Interpace Biosciences’ stock price, you can compare it with its competitors and the financial market. You may also assess how Interpace Biosciences will reduce portfolio volatility if you add it to your portfolios.
